Investigating mTOR signaling pathway and sirolimus response in Benign lymphangioendothelioma
The activation of mTOR signaling pathway is implicated in the pathogenesis of benign lymphangioendothelioma, suggesting a potential similarity in the underlying mechanisms with lymphatic malformations. The mTOR inhibitor sirolimus demonstrated promising therapeutic efficacy, accompanied by a favorable safety profile.
Authors
- X. Ma (ORCID: https://orcid.org/0000-0001-9831-0565)
- Fazhan Ban
- Lei Wang (ORCID: https://orcid.org/0000-0002-2111-5160)
- Daopei Zou (ORCID: https://orcid.org/0000-0001-8312-7178)
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Xijing Hospital (CN)
- Chongqing Medical University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1080/09546634.2025.2511114
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China